HC Wainwright Analysts Cut Earnings Estimates for Genmab A/S

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Investment analysts at HC Wainwright lowered their FY2026 EPS estimates for shares of Genmab A/S in a research note issued on Friday, November 6th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $1.46 per share for the year, down from their previous forecast of $1.51. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.34 EPS, Q1 2027 earnings at $0.22 EPS, Q3 2027 earnings at $0.47 EPS, Q4 2027 earnings at $0.47 EPS and FY2027 earnings at $1.60 EPS.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.20. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.20 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%.

A number of other equities research analysts also recently issued reports on the stock. New Street Research set a $43.00 price target on shares of Genmab A/S in a research note on Wednesday, July 22nd. Morgan Stanley increased their price objective on shares of Genmab A/S from $42.00 to $57.00 and gave the stock an “equal weight” rating in a research report on Friday, October 30th. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. Guggenheim lifted their target price on shares of Genmab A/S from $58.00 to $80.00 and gave the company a “buy” rating in a report on Friday, October 30th. Finally, TD Cowen boosted their target price on Genmab A/S from $43.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.61.

Genmab A/S Trading Up 4.0%

GMAB opened at $55.80 on Tuesday. The stock has a market capitalization of $34.82 billion, a PE ratio of 39.65, a P/E/G ratio of 2.17 and a beta of 0.73. Genmab A/S has a one year low of $23.62 and a one year high of $59.97. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The business’s 50 day moving average price is $39.63 and its 200 day moving average price is $31.22.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. WINTON GROUP Ltd grew its stake in shares of Genmab A/S by 158.9% in the second quarter. WINTON GROUP Ltd now owns 40,900 shares of the company’s stock worth $1,124,000 after acquiring an additional 25,100 shares in the last quarter. Diversify Wealth Management LLC purchased a new stake in shares of Genmab A/S during the first quarter worth $1,216,000. SummitTX Capital L.P. purchased a new stake in shares of Genmab A/S during the first quarter worth $2,263,000. Legacy Wealth Asset Management LLC raised its stake in shares of Genmab A/S by 164.1% in the second quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock valued at $2,806,000 after acquiring an additional 63,484 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Genmab A/S by 26.4% in the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after acquiring an additional 921,700 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases.

The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Genmab operates internationally, with activities across Europe, North America and Asia.